Sanofi: Invest Securities still a buyer; cuts target price

(CercleFinance.com) - Invest Securities maintains its "buy" rating on the Sanofi stock, cutting its target price from 90 euros to 87 euros, given the pharmaceutical group's current valuation, in a report considering the group's outlook for 2018.


While the first half should remain under pressure, the long-awaited return to growth will not occur until the second half of the year (with improving sales of Dupixent, Flubox, Admelog, Kevzara), the analyst monitoring the stock said.

The broker's research team specifies that Bioverativ's closing date will be decisive in adjusting expectations for this year. The next catalyst is expected on 10 March, with the results of ODYSSEY, it stated.

Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.